06:31 AM EDT, 04/24/2024 (MT Newswires) -- Calliditas Therapeutics ( CALT ) said Wednesday that an open-label extension, or OLE, study to its late-stage NefIgArd study showed a treatment response that was consistent with the NefIgArd study's findings.

The open-label extension study enrolled 119 patients, 45 of whom were involved in the previous late-stage study and met its endpoints even among patients who had received a placebo in the earlier trials.

The NefIgArd study achieved primary and key secondary endpoints and was the basis for approval by the US Food and Drug Administration in December, the company said.

Price: 18.43, Change: +0.03, Percent Change: +0.16